Regeneron Pharmaceuticals News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

08.02.18	Regeneron Pharmaceuticals Q4 Income Rises (RTTNews)
08.02.18	Regeneron Reports Fourth Quarter and Full Year 2017 Financial and Operating Results (PR Newswire)
06.02.18	New Molecular Test to Impact Influenza Pandemic Preparedness (PR Newswire)
30.01.18	Camp Bow Wow Showcases Impressive Start to 2018, Ranking #1 in Pet Care on Entrepreneur's Franchise 500 List and More (PR Newswire)
26.01.18	James Flicker Joins Sagent Advisors as a Managing Director and Head of Paper & Forest Products (PR Newswire)
23.01.18	Regeneron to Report Fourth Quarter and Full Year 2017 Financial and Operating Results and Host Conference Call and Webcast on February 8, 2018 (PR Newswire)
23.01.18	Forty of the Nation's Most Promising Young Scientists Named Finalists in Regeneron Science Talent Search 2018 (PR Newswire)
23.01.18	Forty of the Nation's Most Promising Young Scientists Named Finalists in Regeneron Science Talent Search 2018 (PR Newswire)
22.01.18	Regeneron Announces Approval Of DUPIXENT In Japan - Quick Facts (RTTNews)
22.01.18	Regeneron Announces Approval of DUPIXENT® (dupilumab) in Japan for the Treatment of Atopic Dermatitis (PR Newswire)
08.01.18	Infor Releases New Digital Innovation Enabler for Healthcare Industry (PR Newswire)
08.01.18	Sanofi, Regeneron To Expand Investment For Cemiplimab & Dupilumab Development (RTTNews)
08.01.18	Regeneron and Sanofi To Accelerate and Expand Investment for Cemiplimab and Dupilumab Development Programs (PR Newswire)
08.01.18	Regeneron Forms Consortium of Leading Life Sciences Companies to Accelerate Largest Widely-Available 'Big Data' Human Sequencing Resource with UK Biobank (PR Newswire)
21.12.17	Vertek Corporation Partners With VeloCloud to Provide Remote Management & Monitoring (RMM) and Helpdesk Services (PR Newswire)
18.12.17	Regeneron, ISA Pharma Announce Strategic Immuno-Oncology Collaboration (RTTNews)
18.12.17	Regeneron and ISA Pharmaceuticals Announce Strategic Immuno-Oncology Collaboration (PR Newswire)
13.12.17	Regeneron Collaboration Programs Highlighted During Sanofi Analyst Day (PR Newswire)
13.12.17	Regeneron, Sanofi Report Results For PD-1 Antibody Cemiplimab In Advanced CSCC (RTTNews)
13.12.17	Regeneron and Sanofi Announce Positive Topline Pivotal Results for PD-1 Antibody Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma (PR Newswire)
11.12.17	Regeneron Says FDA Accepts SBLA Filing For 12-week Dosing Of Eylea Injection (RTTNews)
11.12.17	Regeneron Announces FDA Acceptance of sBLA Filing for 12-Week Dosing of EYLEA® (aflibercept) Injection for Patients with Wet AMD (PR Newswire)
10.12.17	Repatha & Praluent: A Tale Of Two Rivals... (RTTNews)
30.11.17	TXMD Giving A 2nd Try, PLX On Watch, NAOV's Shield Against Suicide Disease (RTTNews)
29.11.17	Regeneron Pharma, Decibel Announce Collaboration - Quick Facts (RTTNews)
29.11.17	Regeneron and Decibel Therapeutics Announce Strategic Collaboration to Discover and Develop Therapeutics for Hearing Loss and Tinnitus (PR Newswire)
28.11.17	BIIB & ALKS Team Up For MS Drug, REGN's Eylea Combo Fails Again, AEZS Rises (RTTNews)
27.11.17	Regeneron Updates On EYLEA Injection And Nesvacumab Combination Program (RTTNews)
27.11.17	Regeneron Provides Update on EYLEA® (aflibercept) Injection and Nesvacumab (Ang2 Antibody) Combination Program (PR Newswire)
24.11.17	RD Training Systems Is Coming to Salt Lake City, Utah in December 2017 (PR Newswire)
15.11.17	Regeneron Announces Upcoming Investor Conference Presentation (PR Newswire)
08.11.17	Regeneron Pharmaceuticals Earnings Rise 29% In Q3 (RTTNews)
08.11.17	Regeneron Reports Third Quarter 2017 Financial and Operating Results (PR Newswire)
07.11.17	Regeneron and Sanofi to Present New Analyses from the Praluent® (alirocumab) Injection ODYSSEY Clinical Trial Program at the AHA Scientific Sessions 2017 (PR Newswire)
01.11.17	Regeneron to Share Clinical Progress of REGN1979 and Cemiplimab (REGN2810) in B-Cell Lymphomas at the 2017 ASH Annual Meeting (PR Newswire)
31.10.17	Regeneron And Sanofi Say Phase 3 Study On Dupilumab Meets Primary Endpoint (RTTNews)
31.10.17	Dupilumab Significantly Reduced Steroid Use, Asthma Attacks, and Improved Lung Function in Phase 3 Study of People with Severe Steroid-Dependent Asthma (PR Newswire)
27.10.17	Philip Sweet, M.S.N., R.N., PMHCNS-BC, NP is recognized by Continental Who's Who (PR Newswire)
27.10.17	Regeneron's First Global Day of Service Supports Over 100 Non-Profit and Community Organizations (PR Newswire)
24.10.17	IT and Management Consulting Firm Enlightened Selects 5WPR as AOR to Increase Brand Awareness as it Expands into Commercial (PR Newswire)
23.10.17	DBVT Disappoints, GSK Gets Greenlight, AIMT Catches Eyes, FDA Snubs ATRS (RTTNews)
19.10.17	Science Magazine Ranks Regeneron #1 Biopharma Employer for Fifth Time (PR Newswire)
16.10.17	Regeneron Pharma, Sanofi Announce Positive Phase 2 Study Results For Dupilumab (RTTNews)
16.10.17	Regeneron and Sanofi Announce Positive Phase 2 Study Results for Dupilumab in Patients With Active Moderate-to-Severe Eosinophilic Esophagitis (PR Newswire)
11.10.17	Regeneron to Report Third Quarter 2017 Financial and Operating Results and Host Conference Call and Webcast on November 8, 2017 (PR Newswire)
11.10.17	Internationally Acclaimed Writer and Executive Producer of HBO's The Night Of Reveals His Personal Story Detailing the Harsh Realities of Atopic Dermatitis (PR Newswire)
05.10.17	Appellate Court Orders a New Trial and Vacates Permanent Injunction in Ongoing Patent Case Regarding Praluent® (alirocumab) (PR Newswire)
03.10.17	VOXX International Corporation Sets Date For Its Fiscal 2018 Second Quarter Results And Conference Call (PR Newswire)
02.10.17	Regeneron Announces New Collaborations with HHS to Develop Antibodies Against Ebola, Influenza and Multiple Other Emerging Pathogens (PR Newswire)
28.09.17	Sanofi, Regeneron: Dupixent Gets EU Approval To Treat Atopic Dermatitis (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

17.12.24		Schwacher Wochentag in New York: NASDAQ 100 verbucht letztendlich Abschläge
17.12.24		Minuszeichen in New York: NASDAQ 100 verliert nachmittags
17.12.24		Zurückhaltung in New York: NASDAQ 100 präsentiert sich schwächer
12.12.24		Schwache Performance in New York: NASDAQ 100 zeigt sich schlussendlich schwächer
12.12.24		Angespannte Stimmung in New York: NASDAQ 100 präsentiert sich schwächer
12.12.24		Schwacher Handel: NASDAQ 100 am Mittag in der Verlustzone
05.12.24		Börse New York in Rot: NASDAQ 100 zum Ende des Donnerstagshandels schwächer
19.11.24		Zuversicht in New York: NASDAQ 100 mit positivem Vorzeichen

17.12.24

Schwacher Wochentag in New York: NASDAQ 100 verbucht letztendlich Abschläge

17.12.24

Minuszeichen in New York: NASDAQ 100 verliert nachmittags

17.12.24

Zurückhaltung in New York: NASDAQ 100 präsentiert sich schwächer

12.12.24

Schwache Performance in New York: NASDAQ 100 zeigt sich schlussendlich schwächer

12.12.24

Angespannte Stimmung in New York: NASDAQ 100 präsentiert sich schwächer

12.12.24

Schwacher Handel: NASDAQ 100 am Mittag in der Verlustzone

05.12.24

Börse New York in Rot: NASDAQ 100 zum Ende des Donnerstagshandels schwächer

19.11.24

Zuversicht in New York: NASDAQ 100 mit positivem Vorzeichen

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

CieFinRichemont	137.35	1.40 %	K V
Sonova Hldg	297.30	1.29 %	K V
Logitech Intl	74.86	1.22 %	K V
Nestle	75.22	1.02 %	K V
Alcon	76.32	0.95 %	K V
UBS Group	28.17	-0.67 %	K V
Swiss Re	131.95	-0.68 %	K V
Geberit	533.80	-0.78 %	K V
Lonza Grp	541.40	-0.81 %	K V
Kuehne+Nagel Int	202.60	-1.65 %	K V

Nachrichten zu Regeneron Pharmaceuticals Inc.

Aktien Top/Flop

Regeneron Pharmaceuticals Peer Group Nachrichten

Meistgelesene Nachrichten